(Q38785024)

6 September 2017

title

Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals (English)

1 reference

non-24-hour sleep-wake disorder

6 September 2017

1 reference

1 reference

Gillian M Keating

1 reference

6 September 2017

publication date

22 March 2016

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

page(s)

461-468

1 reference

Non-24-Hour Sleep-Wake Rhythm Disorder in Sighted and Blind Patients

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Phototransduction by retinal ganglion cells that set the circadian clock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Human tau in an ultradian light-dark cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Stability, precision, and near-24-hour period of the human circadian pacemaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Blacks (African Americans) have shorter free-running circadian periods than whites (Caucasian Americans)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular S

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Tasimelteon: a selective and unique receptor binding profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Absolute Bioavailability of Tasimelteon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Entraining the free-running circadian clocks of blind people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Melatonin administration can entrain the free-running circadian system of blind subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Entrainment of free-running circadian rhythms by melatonin in blind people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0330-Y

Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27003694

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27003694

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Light, melatonin and the sleep-wake cycle

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27003694

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40263-016-0330-Y

1 reference

6 September 2017

1 reference